Dean F. Bajorin, MD, of Memorial Sloan Kettering Cancer Center, summarizes a panel discussion on this important topic.
Toni Choueiri, MD, of the Dana-Farber Cancer Institute, summarizes key points from a session he chaired on clear and non-clear cell renal cancer, including information on molecular genetics and its impact on treatment, how to treat patients with non-clear cell histology, and the best strategy for treating clear cell cancer.
Maha Hussain, MD, of the University of Michigan, gives her expert perspective on changes in the treatment of hormone-naive disease.
Fred Saad, MD, of the University of Montreal, summarizes his session on the latest treatment developments in prostate cancer, including the role of chemotherapy in hormone-sensitive disease. To see the French language version of this video, click here.
Fred Saad, MD, of the University of Montreal, summarizes in French his session on the latest treatment developments in prostate cancer, including the role of chemotherapy in hormone-sensitive disease.
Paul L. Nguyen, MD, of Dana-Farber Cancer Institute, discusses this phase III trial in which prostate cancer patients were given antiandrogen therapy with bicalutamide during and after salvage radiation therapy following radical prostatectomy and an elevated PSA (Abstract 3).
